profit from every $100 of sales.
$0$100
Mangoceuticals
$0.20+5.34% today
-94.2% in 1 year
1-year low $0.191-year high $3.52
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Mangoceuticals sold, what it kept, and what it did with the cash.
Sales went from $8,939 in 2022 to $456,021 in 2025, with -$20.6 million of profit last year.
SalesProfit
Mangoceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Mangoceuticals | No profit yet | ||
 GE HealthCare Technologies | 17.9× · Fair price | ||
 Tempus AI | No profit yet | ||
 BrightSpring Health Services | 75.8× · Very expensive | ||
 HealthEquity | 39.6× · Expensive |
AI analysis
An AI analyst reads Mangoceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 1 | 1 | 0 | |
| 0 | 0 | 0 | 0 | |
| -2 | -9 | -9 | -19 | |
| -2 | -9 | -8 | -19 | |
| -2 | -9 | -9 | -21 | |
| -1.96 | -8.58 | -4.80 | -2.17 | |
| 54.3% | 59.0% | 61.7% | 54.9% | |
| -22,279.7% | -1,260.3% | -1,411.6% | -4,200.5% | |
| -22,352.1% | -1,259.4% | -1,413.6% | -4,526.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1 | 1 | 15 | 16 |
| Cash | 1 | 1 | 0 | 1 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 0 | 0 | 1 | 1 |
| 1 | 1 | 14 | 15 | |
| 1 | 1 | 2 | 10 | |
| -162.7% | -805.6% | -48.5% | -104.6% | |
| -325.4% | -1,189.1% | -62.4% | -135.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1 | -7 | -5 | -6 | |
| 0 | 0 | – | – | |
| -1 | -7 | -5 | -6 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 1 | 0 | 1 |
Valuation
- –
- –
- –
- 0.2×
- 9.7×
- –
- –
- -132.1%
- -466.1%
- 0.0%
Profitability
- 54.9%
- -4,200.5%
- -4,526.8%
- -4,126.1%
- -123.5%
- -299.9%
- -117.3%
- -128.3%
- -126.0%
- –
Growth
- +270.9%
- –
- −20.3%
- –
- +78.2%
Financial health
- -0.1×
- 0.02
- 1.9%
- -163.4×
- 1.74
- 1.74
- 0.03
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 889
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 19, 2026 | -0.22 | – | – |
| Apr 1, 2026 | 0.13 | – | – |
| Nov 14, 2025 | -0.69 | – | – |
| Aug 14, 2025 | -0.57 | – | – |
| May 15, 2025 | -1.29 | – | – |
| Mar 20, 2025 | -1.01 | – | – |
| Nov 14, 2024 | -0.99 | – | – |
| Aug 14, 2024 | -1.35 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
68Pass
Philip Fisher
43No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
41No pass
Terry Smith
30No pass
Questions about Mangoceuticals
Is Mangoceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Mangoceuticals AI analysis
What does Mangoceuticals do?
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. It is in Medical - Healthcare Information Services.
Does Mangoceuticals pay a dividend?
No. Mangoceuticals does not pay a dividend at the moment.
Is Mangoceuticals stock halal?
No. Mangoceuticals does not pass our halal screen: its cash and confirmed interest-bearing investments are 34% of its market value, at or above the 33% limit. How we check
How has Mangoceuticals stock done over the past year?
Down 94.2% over the past twelve months, to $0.20. It traded between $0.19 and $3.52 and is 94.3% below its high.
Who are Mangoceuticals's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, Tempus AI, BrightSpring Health Services and HealthEquity. The peers table on this page compares their profit, growth and price with Mangoceuticals's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.